NLTX (Neoleukin Therapeutics) Institutional Ownership : 14.63% (As of Oct. 31, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Neoleukin Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Neoleukin Therapeutics's institutional ownership is 14.63%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Neoleukin Therapeutics's Insider Ownership is 39.43%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Neoleukin Therapeutics's Float Percentage Of Total Shares Outstanding is 99.98%.

Neoleukin Therapeutics Institutional Ownership Historical Data

The historical data trend for Neoleukin Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neoleukin Therapeutics Institutional Ownership Chart

Neoleukin Therapeutics Historical Data

The historical data trend for Neoleukin Therapeutics can be seen below:

	2023-02-28	2023-03-31	2023-04-30	2023-05-31	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30
Institutional Ownership	5.61	5.46	5.41	5.03	4.90	4.89	4.88	4.92	3.66	14.63

Neoleukin Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Neoleukin Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neoleukin Therapeutics Inc (NAS:NLTX) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

188 East Blaine Street, Suite 450, Seattle, WA, USA, 98102

Website

https://www.neoleukin.com

Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefits over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, which is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.

Executives

Baker Bros. Advisors Lp	10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Sean Michael Smith	officer: Principal Accounting Officer	C/O NEOLEUKIN THERAPEUTICS, INC., 188 E. BLAINE STREET, SUITE 450, SEATTLE WA 98102
Priti Patel	officer: Chief Medical Officer	C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450, SEATTLE WA 98102
Erin Lavelle	director	C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Donna Cochener	officer: General Counsel, SVP Legal	C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, SUITE 450, SEATTLE WA 98102
Rohan Palekar	director	201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Jonathan G Drachman	director, officer: See Remarks	21823 30TH DRIVE SE, BOTHELL WA 98021
Carl Walkey	officer: Senior Vice President	C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Robert Ho	officer: Chief Financial Officer	360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Holly Vance	officer: General Counsel	C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE E., SEATTLE WA 98102
Martin Babler	director	C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Erin M. Lavelle	director	360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Redmile Group, Llc	10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Jeremy Green	10 percent owner	45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Sarah B. Noonberg	director	331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080